Nifty
Sensex
:
:
12968.95
44149.72
-18.05 (-0.14%)
-110.02 (-0.25%)

Pharmaceuticals & Drugs - Global

Rating :
62/99  (View)

BSE: 532531 | NSE: STAR

764.10
13.75 (1.83%)
27-Nov-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  754.00
  •  773.90
  •  733.20
  •  750.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1480398
  •  11311.72
  •  773.90
  •  268.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,851.28
  • 92.00
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 8,575.92
  • 1.83%
  • 2.55

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 29.69%
  • 0.00%
  • 15.14%
  • FII
  • DII
  • Others
  • 26.96%
  • 15.14%
  • 13.07%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 0.82
  • -3.76

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 6.04
  • 16.70

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 4.87
  • -40.49

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.76
  • 23.25
  • 10.38

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.99
  • 2.46
  • 1.69

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.54
  • 14.58
  • 12.50

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
794
715
11%
782
686
14%
619
616
0%
732
570
29%
Expenses
636
568
12%
631
565
12%
554
524
6%
552
509
8%
EBITDA
157
147
7%
151
121
25%
65
92
-30%
181
61
196%
EBIDTM
20%
20%
19%
18%
14%
14%
25%
11%
Other Income
18
14
26%
16
10
58%
18
17
4%
14
10
41%
Interest
37
40
-9%
37
35
4%
40
23
73%
40
22
81%
Depreciation
53
42
26%
49
43
15%
45
30
53%
43
28
56%
PBT
98
162
-39%
126
46
172%
-173
72
-
127
35
268%
Tax
6
7
-17%
3
3
5%
-10
-8
-
11
0
-
PAT
92
154
-40%
123
43
184%
-163
80
-
116
35
233%
PATM
12%
22%
16%
6%
7%
7%
16%
6%
EPS
10.31
17.22
-40%
13.71
4.82
184%
-18.15
8.91
-
12.92
3.88
233%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Net Sales
2,926
2,981
3,108
3,344
3,826
2,862
1,196
1,341
962
2,550
1,696
Net Sales Growth
13%
-4%
-7%
-13%
34%
139%
-11%
39%
-62%
50%
 
Cost Of Goods Sold
5,516
1,122
1,085
1,379
1,281
1,502
560
715
492
1,264
806
Gross Profit
-2,589
1,859
2,023
1,966
2,545
1,360
635
626
470
1,286
890
GP Margin
-88%
62%
65%
59%
67%
48%
53%
47%
49%
50%
52%
Total Expenditure
2,372
2,471
2,812
3,109
3,309
2,482
967
1,118
861
2,059
1,369
Power & Fuel Cost
-
64
54
51
34
77
16
19
13
54
30
% Of Sales
-
2%
2%
2%
1%
3%
1%
1%
1%
2%
2%
Employee Cost
-
443
329
434
419
358
172
157
120
303
220
% Of Sales
-
15%
11%
13%
11%
12%
14%
12%
13%
12%
13%
Manufacturing Exp.
-
211
151
116
137
119
41
36
44
90
64
% Of Sales
-
7%
5%
3%
4%
4%
3%
3%
5%
4%
4%
General & Admin Exp.
-
192
150
194
173
199
86
66
58
182
159
% Of Sales
-
6%
5%
6%
5%
7%
7%
5%
6%
7%
9%
Selling & Distn. Exp.
-
137
111
209
161
130
61
67
40
116
88
% Of Sales
-
5%
4%
6%
4%
5%
5%
5%
4%
5%
5%
Miscellaneous Exp.
-
302
930
725
1,104
97
29
58
94
50
88
% Of Sales
-
10%
30%
22%
29%
3%
2%
4%
10%
2%
0%
EBITDA
554
510
297
236
517
381
229
223
101
491
327
EBITDA Margin
19%
17%
10%
7%
14%
13%
19%
17%
10%
19%
19%
Other Income
65
67
323
921
398
102
39
60
34
32
70
Interest
154
156
79
196
183
168
47
109
79
195
147
Depreciation
191
188
172
194
199
131
64
56
31
104
64
PBT
178
233
368
766
533
184
156
118
24
223
186
Tax
10
18
14
21
51
42
148
41
11
39
45
Tax Rate
6%
12%
4%
3%
10%
30%
99%
45%
2%
14%
24%
PAT
168
144
370
681
399
113
2
51
712
224
122
PAT before Minority Interest
175
138
376
701
446
100
1
51
713
234
141
Minority Interest
7
6
-5
-20
-46
14
1
0
-1
-10
-19
PAT Margin
6%
5%
12%
20%
10%
4%
0%
4%
74%
9%
7%
PAT Growth
-46%
-61%
-46%
71%
253%
7,111%
-97%
-93%
217%
83%
 
EPS
18.78
16.03
41.33
76.04
44.57
12.64
0.18
5.68
79.51
25.05
13.67

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Shareholder's Funds
2,527
2,649
2,464
2,749
2,658
1,145
1,007
2,026
1,371
1,283
Share Capital
90
90
90
89
89
60
60
59
58
58
Total Reserves
2,432
2,552
2,365
2,651
2,563
1,084
947
1,964
1,310
1,223
Non-Current Liabilities
814
2,343
2,067
2,049
2,760
286
306
901
1,133
2,013
Secured Loans
602
1,806
1,551
1,623
2,615
250
274
731
1,054
1,387
Unsecured Loans
2
0
0
15
12
17
1
0
0
622
Long Term Provisions
64
52
17
25
14
6
17
57
66
0
Current Liabilities
2,545
2,662
1,899
3,104
1,892
1,020
707
1,797
2,792
924
Trade Payables
798
889
712
774
775
234
262
463
585
420
Other Current Liabilities
354
248
130
819
348
502
127
652
1,370
305
Short Term Borrowings
1,229
1,339
944
1,394
700
203
225
600
685
0
Short Term Provisions
164
186
113
117
68
80
93
83
152
199
Total Liabilities
5,953
7,807
6,585
8,035
7,360
2,469
2,096
4,796
5,342
4,492
Net Block
2,026
3,570
2,903
2,909
2,679
701
555
3,017
3,188
2,328
Gross Block
2,534
4,049
3,229
3,186
2,825
1,081
907
3,514
3,645
2,627
Accumulated Depreciation
509
479
326
277
147
379
353
498
457
298
Non Current Assets
3,581
4,758
4,101
4,243
3,845
1,040
788
3,384
3,711
2,521
Capital Work in Progress
413
453
620
780
815
171
99
241
285
191
Non Current Investment
503
494
350
316
127
69
42
0
0
2
Long Term Loans & Adv.
208
224
197
223
202
97
90
119
230
0
Other Non Current Assets
431
17
31
16
23
2
1
7
9
0
Current Assets
2,372
3,049
2,484
3,792
3,515
1,429
1,309
1,411
1,625
1,960
Current Investments
119
285
311
1,280
1,214
561
401
0
0
0
Inventories
783
874
552
733
613
208
176
442
480
312
Sundry Debtors
932
987
882
996
1,033
390
364
483
538
384
Cash & Bank
237
517
303
329
312
147
231
166
260
339
Other Current Assets
302
137
139
210
343
124
136
320
347
925
Short Term Loans & Adv.
218
249
296
244
98
54
79
44
92
850
Net Current Assets
-173
386
584
688
1,623
410
601
-386
-1,166
1,037
Total Assets
5,953
7,807
6,585
8,035
7,360
2,469
2,096
4,796
5,342
4,492

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Cash From Operating Activity
205
60
187
288
73
83
-272
134
457
324
PBT
49
344
706
497
146
992
2,890
949
273
186
Adjustment
527
95
-275
191
346
-757
-2,775
-416
114
179
Changes in Working Capital
-326
-323
-191
-341
-342
-96
-261
-311
129
-2
Cash after chg. in Working capital
250
116
241
347
150
139
-146
223
515
363
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-45
-56
-54
-59
-77
-56
-126
-89
-58
-39
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
1,306
-148
583
-687
-2,225
52
4,077
807
-656
-941
Net Fixed Assets
-115
-48
677
-237
-536
-67
-119
-38
-18
-43
Net Investments
-17
-383
748
-143
-1,479
78
249
-509
78
654
Others
1,438
283
-842
-307
-210
40
3,947
1,353
-716
-1,552
Cash from Financing Activity
-1,709
194
-1,016
338
2,944
-421
-3,319
-990
89
850
Net Cash Inflow / Outflow
-198
106
-246
-60
792
-286
487
-49
-110
233
Opening Cash & Equivalents
366
256
515
1,111
299
586
132
212
325
79
Closing Cash & Equivalent
182
366
256
515
1,111
298
586
132
212
325

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Book Value (Rs.)
282
295
274
306
297
192
169
344
233
220
ROA
2%
5%
10%
6%
2%
0%
1%
14%
5%
4%
ROE
5%
15%
27%
17%
5%
0%
3%
42%
18%
14%
ROCE
6%
9%
16%
11%
8%
11%
8%
21%
13%
12%
Fixed Asset Turnover
1.50
1.17
1.04
1.27
1.47
1.21
0.61
0.27
0.82
0.72
Receivable days
71
80
102
97
91
115
115
193
66
86
Inventory Days
61
61
70
64
52
58
84
175
56
59
Payable days
139
147
116
117
76
77
113
253
93
120
Cash Conversion Cycle
-6
-6
56
44
68
96
86
115
30
25
Total Debt/Equity
0.78
1.22
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
Interest Cover
2
6
5
4
2
4
2
10
2
2

News Update


  • Strides Pharma Science’s arm gets USFDA approval for Prednisone Tablets
    23rd Nov 2020, 13:41 PM

    The product will be manufactured at the company’s flagship facility at Bengaluru

    Read More
  • Strides Pharma’s arm gets USFDA’s nod for Ethacrynic Acid Tablets
    20th Oct 2020, 12:00 PM

    The company has 126 cumulative ANDA filings with USFDA of which 92 ANDAs have been approved and 34 are pending approval

    Read More
  • Strides Pharma’s arm gets USFDA nod for Butalbital, Acetaminophen, Caffeine Tablets
    22nd Sep 2020, 12:58 PM

    The product will be marketed by Strides Pharma Inc. in the US market

    Read More
  • Strides unveils SteriScience as its dedicated arm for sterile injectables
    14th Sep 2020, 14:37 PM

    The transaction with Brooks is subject to approval from the shareholders of Brooks

    Read More
  • Strides Pharma’s arm gets USFDA’s nod for Prednisone Tablets
    3rd Sep 2020, 16:00 PM

    The US market for Prednisone Tablets USP, 1 mg is approximately $12 million

    Read More
  • Strides Pharma Science’s arm gets USFDA’s approval for Ursodiol Tablets
    21st Aug 2020, 12:40 PM

    The product will be manufactured at the company’s flagship facility at Bengaluru

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.